JP2003500348A5 - - Google Patents

Download PDF

Info

Publication number
JP2003500348A5
JP2003500348A5 JP2000619406A JP2000619406A JP2003500348A5 JP 2003500348 A5 JP2003500348 A5 JP 2003500348A5 JP 2000619406 A JP2000619406 A JP 2000619406A JP 2000619406 A JP2000619406 A JP 2000619406A JP 2003500348 A5 JP2003500348 A5 JP 2003500348A5
Authority
JP
Japan
Prior art keywords
ssri
measurement
hours
released
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000619406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003500348A (ja
Filing date
Publication date
Priority claimed from IE19990406A external-priority patent/IE990406A1/en
Application filed filed Critical
Priority claimed from PCT/IE2000/000060 external-priority patent/WO2000071099A1/en
Publication of JP2003500348A publication Critical patent/JP2003500348A/ja
Publication of JP2003500348A5 publication Critical patent/JP2003500348A5/ja
Pending legal-status Critical Current

Links

JP2000619406A 1999-05-20 2000-05-10 多粒子状制御放出選択的セロトニン再吸収阻害剤製剤 Pending JP2003500348A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13502899P 1999-05-20 1999-05-20
US60/135,028 1999-05-20
IE990406 1999-05-20
IE19990406A IE990406A1 (en) 1999-05-20 1999-05-20 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
PCT/IE2000/000060 WO2000071099A1 (en) 1999-05-20 2000-05-10 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations

Publications (2)

Publication Number Publication Date
JP2003500348A JP2003500348A (ja) 2003-01-07
JP2003500348A5 true JP2003500348A5 (https=) 2007-03-22

Family

ID=26320248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000619406A Pending JP2003500348A (ja) 1999-05-20 2000-05-10 多粒子状制御放出選択的セロトニン再吸収阻害剤製剤

Country Status (16)

Country Link
EP (2) EP1852111A1 (https=)
JP (1) JP2003500348A (https=)
AT (1) ATE367153T1 (https=)
AU (1) AU782059B2 (https=)
CA (2) CA2698347A1 (https=)
CY (1) CY1107750T1 (https=)
CZ (1) CZ302388B6 (https=)
DE (1) DE60035579T2 (https=)
DK (1) DK1178780T3 (https=)
DZ (1) DZ3256A1 (https=)
ES (1) ES2290027T3 (https=)
HU (1) HU229569B1 (https=)
PT (1) PT1178780E (https=)
RU (1) RU2275191C2 (https=)
SK (1) SK286865B6 (https=)
WO (1) WO2000071099A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
BR0100334A (pt) * 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante
JP2005512997A (ja) * 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ タムスロシン錠
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
ATE336988T1 (de) 2003-07-30 2006-09-15 Pharmathen Sa Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
JP2008231025A (ja) * 2007-03-20 2008-10-02 Kyowa Yakuhin Kogyo Kk マレイン酸フルボキサミン錠剤
WO2018206923A1 (en) * 2017-05-11 2018-11-15 Opal Ip Limited Novel formulations
WO2025111679A1 (pt) * 2023-11-30 2025-06-05 Prati, Donaduzzi & Cia Ltda Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
FR2754710B1 (fr) * 1996-10-22 1998-12-31 Prographarm Lab Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
UA63953C2 (uk) * 1997-07-01 2004-02-16 Пфайзер Продактс Інк. Дозована форма уповільненого вивільнення, що містить сертралін, (варіанти) та спосіб лікування (варіанти)
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation

Similar Documents

Publication Publication Date Title
AU760006B2 (en) Method for making granules with masked taste and instant release of the active particle
JP2003500348A5 (https=)
CA1303504C (en) Pharmaceutical formulation containing acrivastine
US7897173B2 (en) Sustained-release, oral pharmaceutical formulations and methods of making and using same
JP2001520985A5 (https=)
JP5661281B2 (ja) 良好な水溶解性を有する作用物質のための作用物質の制御送達を有する医薬組成物
JP2000109426A (ja) 薬剤的に活性な粒子の調製方法
JP2002541092A (ja) メチルフェニデートのパルス性送達のための薬学的投薬形態
JP2002526401A (ja) 制御された作用物質放出性を有する被覆された医薬品形
NZ709754A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
JP2008280351A5 (https=)
JPH11509539A (ja) パロキセチン制御放出組成物
JP2007507553A5 (https=)
CA2374039A1 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
JP2005528430A (ja) 組合せ即時放出および制御放出レボドーパ／カルビドーパ剤型
RU2001134614A (ru) Состоящие из множества частиц фармацевтические составы с контролируемым высвобождением избирательного ингибитора повторного поглощения серотонина
EP0212746A2 (en) Drug particles having constant release
CA1323837C (en) Solid, rapidly disintegrating dosage form
AU2005226927B2 (en) Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)
HU224193B1 (hu) Késleltetett és időzített hatóanyag-felszabadulást biztosító multipartikuláris gyógyszerforma
RU2006118696A (ru) Суспензии анальгетиков с контролируемым высвобождением
CA2370355A1 (en) Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
JP2004175781A (ja) タムスロシン又は薬学的に許容されるその塩を活性成分とする徐放性排尿障害治療剤
US7662805B2 (en) Oral antidepressant formulation
JP2007509838A (ja) 作用の発現を促進するアセチルサルチル酸を含んで成る経口抗うつ製剤